Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Prudential Financial Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Prudential Financial Inc trades at $122.19 (market cap $42.13B). The key difference: Prudential Financial Inc is far larger — about 4.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Prudential Financial Inc pays a 4.59% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PRU | |
|---|---|---|
Market Cap | $9.39B | $42.13B |
Sector | Health | Financials |
52-Week High | $356.25 | $123.93 |
52-Week Low | $241.71 | $92.00 |
Enterprise Value | $9.14B | $70.91B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Prudential Financial (PRU) trades at $121.28, down 0.18% today, with a bullish technical signal from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 11 and net income margin of 6.04%, supported by Q2 2026 earnings beating estimates. Recent news highlights strategic refocusing and institutional buying interest, though China tax concerns caused temporary volatility.
Outlook remains positive due to earnings beats and capital-light strategy, but risks include interest rate sensitivity and geopolitical exposure. Analyst consensus is cautious with a $110 price target below current levels, suggesting limited upside despite solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
